Anteris Exits v2v Partnership With $400K Break Fee to Refocus on DurAVR Rollout
Anteris Technologies exits v2vmedtech partnership with minimal financial impact
Anteris Technologies has elected to discontinue development contributions under its 2023 partnership with v2vmedtech, marking a strategic capital allocation decision as the company refocuses resources on its flagship DurAVR® Transcatheter Heart Valve programme. The termination, which occurred after completing Stage 1 and during Stage 2 of the development programme, will result in a one-time break fee of US$400,000 with no ongoing financial obligations. Management has assessed that the decision will not materially affect the company’s consolidated financial position or liquidity, positioning the exit as a disciplined approach to preserving capital for core commercialisation efforts.
The termination notice was provided on 28 April 2026 (US time), officially ending Anteris’ commitment under the Contribution and Stock Purchase Agreement originally signed on 18 April 2023. The structured exit demonstrates management’s willingness to withdraw from adjacent programmes when strategic priorities shift, particularly as the company advances its lead product through critical regulatory and commercial milestones.
When big ASX news breaks, our subscribers know first
What the termination means for Anteris shareholders
Following the termination, v2vmedtech’s initial shareholders now have two contractual options available to them regarding Anteris’ equity interest in the venture. Anteris has no further funding obligations beyond the US$400,000 break fee, which v2v will use for continued development of the technology. v2v has not yet communicated which option it intends to pursue.
The two shareholder election options are:
- Acquire all of Anteris’ equity interest in v2v for an amount equal to Anteris’ aggregate contributions to date
- Reduce Anteris’ equity interest to a capped minority ownership percentage as specified in the original agreement
Either outcome removes ongoing capital commitment from the Anteris balance sheet whilst providing a defined, capped exit cost with no trailing obligations. The structured nature of these options ensures an orderly resolution without litigation risk, allowing management to maintain focus on DurAVR® commercialisation activities.
Understanding development contribution agreements in medtech
Development contribution agreements are common structures in early-stage medical device partnerships, allowing companies to collaborate on technology development whilst maintaining strategic flexibility. These arrangements typically involve staged development programmes where funding is released incrementally as specific milestones are achieved, rather than committing all capital upfront.
Companies structure these agreements with exit mechanisms between stages specifically to enable strategic reassessment as programmes progress. Pre-agreed break fee provisions, such as the US$400,000 amount in this case, provide both parties with certainty around exit costs and obligations, avoiding the need for complex renegotiation or potential disputes when one party elects to discontinue participation.
Investors should understand that exiting staged development agreements is a standard capital allocation tool available to management, particularly when resource prioritisation shifts towards more advanced programmes. The existence of exit mechanisms does not necessarily indicate technology failure; rather, it reflects prudent contract design that accommodates evolving strategic priorities over multi-year development timelines.
Anteris’ strategic focus remains on DurAVR® heart valve commercialisation
Anteris’ core business centres on the DurAVR® Transcatheter Heart Valve, designed to treat aortic stenosis through a biomimetic approach that aims to replicate normal aortic blood flow. The balloon-expandable valve is constructed using a single piece of moulded ADAPT® tissue, Anteris’ proprietary anti-calcification tissue technology that has been FDA-cleared and used clinically for over 10 years.
| Technology Component | Status | Clinical History |
|---|---|---|
| ADAPT® Tissue | FDA-cleared | Over 10 years clinical use |
| Patient Distribution | Worldwide deployment | Over 55,000 patients |
| DurAVR® THV System | Commercialisation phase | Includes ComASUR® Delivery System |
Company Statement
“The Company does not expect the discontinuation of contributions under the Agreement and the termination of the Development Agreement to have a material adverse effect on its consolidated financial position or liquidity.”
The v2v partnership represented an adjacent programme rather than a critical component of the DurAVR® commercialisation pathway. By exiting this development commitment, Anteris preserves capital resources to support the lead product’s market development activities, particularly as the company advances through regulatory processes and prepares for commercial launch activities.
Key terms of the v2v agreement termination
| Term | Detail | Status | Investor Note |
|---|---|---|---|
| Break fee | US$400,000 | Payable to v2v | One-time cost, no ongoing obligation |
| Development contributions | Discontinued | Effective immediately | No further capital outflows |
| Equity interest | Pending v2v election | Two options available | Outcome to be communicated |
| Development Agreement | Terminates | Upon break fee payment | Clean contractual exit |
The termination structure provides clarity for balance sheet planning whilst eliminating uncertainty around future funding requirements. The US$400,000 break fee represents the maximum financial exposure Anteris faces from this exit decision, with v2v’s subsequent election determining whether the company retains any residual equity position in the venture.
The next major ASX story will hit our subscribers first
What comes next for Anteris
v2vmedtech has not yet informed Anteris which of the two available equity options it intends to pursue. Investors should monitor for further updates regarding the final equity position outcome, which will determine whether Anteris retains a capped minority stake or fully exits its investment in v2v through a buyback arrangement.
Management has reiterated that it does not expect material impact on the company’s financial position or liquidity regardless of which option v2v selects. The defined nature of both potential outcomes provides certainty around the financial implications of the partnership exit.
The near-term catalyst for shareholders is v2v’s election decision, which will finalise Anteris’ exposure to the venture. The capped financial commitment ensures that balance sheet planning can proceed with clarity as the company continues advancing DurAVR® commercialisation activities through 2026 and beyond.
Don’t Miss the Next MedTech Breakthrough
Join 20,000+ investors receiving FREE ASX healthcare and biotech alerts delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get breaking ASX announcements the moment they hit the market, with expert coverage already done for you.